Related Experiment Videos
Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy
M Otsu1, S M Anderson, D M Bodine
1Clinical Gene Therapy Branch, NHGRI, NIH, Bethesda, Maryland 20892-1851, USA.
Summary
Gene therapy using retroviral vectors successfully corrected X-linked severe combined immunodeficiency (XSCID) in mice. Stem cell gene correction restored immune cell development and function, showing promise for human clinical trials.
Area of Science:
- Immunology
- Gene Therapy
- Hematology
Background:
- Mutations in the common gamma chain (gammac) lead to X-linked severe combined immunodeficiency (XSCID).
- XSCID is a severe primary immunodeficiency disease, making it a candidate for gene therapy.
- Current treatments for XSCID have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the feasibility of stem cell gene correction for X-linked severe combined immunodeficiency (XSCID) using a murine model.
- To assess the efficacy of retroviral-mediated gene transfer in restoring immune function in XSCID mice.
- To investigate the potential for in vivo selective advantage of gene-corrected cells.
Main Methods:
- XSCID bone marrow (BM) cells were genetically modified using a retroviral vector encoding the murine gammac (mgammac).
- Transduced cells were engrafted into irradiated XSCID recipient mice.
- Immune cell populations, transgene expression (RNA and protein), and immune responses were analyzed post-transplantation.
Main Results:
- Transplanted mice exhibited the development of mature B cells, naive T cells, and natural killer (NK) cells, which were absent in untreated controls.
- The mgammac transgene was successfully detected in all treated mice, with demonstrated expression in newly developed lymphocytes.
- Treated mice showed restored T cell proliferation and antigen-specific antibody production, with four out of seven animals displaying an increase in transgene-positive cells, suggesting selective advantage.
Conclusions:
- Retroviral-mediated gene transfer is a feasible strategy for correcting X-linked severe combined immunodeficiency (XSCID) in a murine model.
- Stem cell gene correction can restore critical immune cell populations and functions in XSCID.
- These findings support the potential application of similar gene therapy strategies in human clinical trials for XSCID.